Published in PLoS One on February 04, 2013
FAD synthesis and degradation in the nucleus create a local flavin cofactor pool. J Biol Chem (2013) 0.83
Cytotoxicity Study on Luminescent Nanocrystals Containing Phospholipid Micelles in Primary Cultures of Rat Astrocytes. PLoS One (2016) 0.75
Inhibitory Effect of Aqueous Extracts from Marine Sponges on the Activity and Expression of Gelatinases A (MMP-2) and B (MMP-9) in Rat Astrocyte Cultures. PLoS One (2015) 0.75
Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol (1980) 11.52
Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci (2001) 4.99
Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep Biochem (1972) 4.87
Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol (1997) 4.09
Matrix metalloproteinases in neuroinflammation. Glia (2002) 3.51
T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol (1995) 1.78
Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett (1995) 1.54
Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J Exp Med (1996) 1.34
Electrophoresis buffers for polyacrylamide gels at various pH. Anal Biochem (1982) 1.32
A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. Proc Natl Acad Sci U S A (1999) 1.31
Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology (1999) 1.31
Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol (1992) 1.22
Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: links to HIV-1 dementia. Glia (2003) 1.22
TNF-alpha- and IFN-gamma-mediated signal transduction pathways: effects on glial cell gene expression and function. FASEB J (1995) 1.22
TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res (1992) 1.21
Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators. J Neurol Sci (2007) 1.18
The expression of tissue-type plasminogen activator, matrix metalloproteases and endogenous inhibitors in the central nervous system in multiple sclerosis: comparison of stages in lesion evolution. J Neuropathol Exp Neurol (1996) 1.18
Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. Brain (2001) 1.10
Upregulation of calpain correlates with increased neurodegeneration in acute experimental auto-immune encephalomyelitis. J Neurosci Res (2005) 1.08
Protein co-expression with axonal injury in multiple sclerosis plaques. Acta Neuropathol (2006) 1.07
Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. Proc Natl Acad Sci U S A (1998) 1.07
A novel calpain inhibitor for the treatment of acute experimental autoimmune encephalomyelitis. J Neuroimmunol (2006) 1.05
Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun (1993) 1.05
Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult Scler (2002) 1.04
Probing cytokines, chemokines and matrix metalloproteinases towards better immunotherapies of multiple sclerosis. Cytokine Growth Factor Rev (2011) 1.03
Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol (2003) 1.01
Calpain as a novel target for treating acute neurodegenerative disorders. Neurol Res (1995) 1.01
Calpeptin attenuated inflammation, cell death, and axonal damage in animal model of multiple sclerosis. J Neurosci Res (2010) 0.99
Calpain expression and infiltration of activated T cells in experimental allergic encephalomyelitis over time: increased calpain activity begins with onset of disease. J Neuroimmunol (2002) 0.97
Pathophysiological role of calpain in experimental demyelination. J Neurosci Res (1999) 0.96
Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia. Brain (2003) 0.96
Calpain secreted by activated human lymphoid cells degrades myelin. J Neurosci Res (1995) 0.95
IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology (2003) 0.92
Inhibition of calpain attenuates encephalitogenicity of MBP-specific T cells. J Neurochem (2009) 0.90
Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment. Mult Scler (2004) 0.88
Human monocyte-derived dendritic cells produce bioactive gelatinase B: inhibition by IFN-beta. J Interferon Cytokine Res (2001) 0.86
Matrix metalloproteinase-9 and tissue inhibitors of matrix metalloproteinase-1 in plasma of patients co-infected with HCV and HIV. HIV Clin Trials (2002) 0.86
Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Brain (2003) 0.85
Casein zymography of calpains using a 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid-imidazole buffer. Anal Biochem (2002) 0.82
Release of myelin basic protein-degrading proteolytic activity from microglia and macrophages after infection with Theiler's murine encephalomyelitis virus: comparison between susceptible and resistant mice. J Neuroimmunol (1995) 0.80
Case report: DNA fragmentation in glial cells in a cerebral biopsy from a multiple sclerosis patient. Cell Mol Biol (Noisy-le-grand) (1998) 0.78
Inhibition of aquaporin-4 expression in astrocytes by RNAi determines alteration in cell morphology, growth, and water transport and induces changes in ischemia-related genes. FASEB J (2003) 1.06
Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol (2003) 1.04
A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains. Biochim Biophys Acta (2006) 0.93
May diet and dietary supplements improve the wellness of multiple sclerosis patients? A molecular approach. Autoimmune Dis (2011) 0.90
Inhibitory effect of polyunsaturated fatty acids on MMP-9 release from microglial cells--implications for complementary multiple sclerosis treatment. Neurochem Res (2007) 0.89
REXO2 is an oligoribonuclease active in human mitochondria. PLoS One (2013) 0.88
Interferon-beta inhibits the expression of metalloproteinases in rat glial cell cultures: implications for multiple sclerosis pathogenesis and treatment. Mult Scler (2004) 0.88
In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection. PLoS One (2011) 0.84
The mystery of mitochondrial RNases. Biochem Soc Trans (2012) 0.83
FAD synthesis and degradation in the nucleus create a local flavin cofactor pool. J Biol Chem (2013) 0.83
Cationic liposomes target sites of acute neuroinflammation in experimental autoimmune encephalomyelitis. Mol Pharm (2009) 0.82
Structure-dependent inhibition of gelatinases by dietary antioxidants in rat astrocytes and sera of multiple sclerosis patients. Neurochem Res (2011) 0.82
Impact of manganese neurotoxicity on MMP-9 production and superoxide dismutase activity in rat primary astrocytes. Effect of resveratrol and therapeutical implications for the treatment of CNS diseases. Toxicol Sci (2013) 0.81
The pH-dependent unfolding mechanism of P2 myelin protein: an experimental and computational study. J Struct Biol (2005) 0.79
Lipoprotein(a) in the cerebrospinal fluid of neurological patients with blood-cerebrospinal fluid barrier dysfunction. Clin Chem (2006) 0.78
Heterogeneity of serum gelatinases MMP-2 and MMP-9 isoforms and charge variants. J Cell Mol Med (2014) 0.78
The different forms of PNS myelin P0 protein within and outside lipid rafts. J Neurochem (2008) 0.77
Crystals of P2 myelin protein in lipid-bound form. J Struct Biol (2003) 0.76